With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients
- Written by Newsfile
Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients. VELDONA is Very Low-Dose Oral Interferon Alpha, Ainos' proprietary oral lozenge formulation of...
